Fast Track

You have full text access to this OnlineOpen article

RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells

  1. Bodil Bjørndal1,†,*,
  2. Line M. Myklebust1,†,
  3. Ken Roger Rosendal1,
  4. Frøydis D. Myromslien1,
  5. James B. Lorens2,
  6. Garry Nolan3,
  7. Ove Bruland4,
  8. Johan R. Lillehaug1

Article first published online: 5 DEC 2006

DOI: 10.1002/ijc.22373

Issue

International Journal of Cancer

International Journal of Cancer

Volume 120, Issue 5, pages 961–969, 1 March 2007

Additional Information

How to Cite

Bjørndal, B., Myklebust, L. M., Rosendal, K. R., Myromslien, F. D., Lorens, J. B., Nolan, G., Bruland, O. and Lillehaug, J. R. (2007), RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells. Int. J. Cancer, 120: 961–969. doi: 10.1002/ijc.22373

Author Information

  1. 1

    Department of Molecular Biology, University of Bergen, Bergen, Norway

  2. 2

    Department of Biomedicine, University of Bergen, Bergen, Norway

  3. 3

    Department of Immunology and Microbiology, Stanford University School of Medicine, Stanford, CA

  4. 4

    Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway

  1. †

    The first 2 authors contributed equally to this work.

*Department of Molecular Biology, University of Bergen, Bergen, Norway

Publication History

  1. Issue published online: 19 JAN 2007
  2. Article first published online: 5 DEC 2006
  3. Manuscript Accepted: 31 AUG 2006
  4. Manuscript Received: 3 JUL 2006

Funded by

  • Norwegian Cancer Society
  • Norwegian Research Council
  • The Locus on Cancer Research, Faculty of Medicine, University of Bergen

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (746K)

References

  • 1
    Marshall MS. Ras target proteins in eukaryotic cells. Faseb J 1995; 9: 1311–8.
  • 2
    Joneson T, Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med 1997; 75: 587–93.
  • 3
    Schmidt A, Hall MN. Signaling to the actin cytoskeleton. Annu Rev Cell Dev Biol 1998; 14: 305–38.
  • 4
    Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49–139.
  • 5
    Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9: 180–6.
  • 6
    Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24: 21–44.
  • 7
    Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994; 265: 966–70.
  • 8
    Behrens A, Jochum W, Sibilia M, Wagner EF. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 2000; 19: 2657–63.
  • 9
    Xiao L, Lang W. A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells. Cancer Res 2000; 60: 400–8.
  • 10
    Potempa S, Ridley AJ. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol Biol Cell 1998; 9: 2185–200.
  • 11
    Mansell A, Khelef N, Cossart P, O'Neill LA. Internalin B activates nuclear factor-κ B via Ras, phosphoinositide 3-kinase, and Akt. J Biol Chem 2001; 276: 43597–603.
  • 12
    Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. Embo J 1996; 15: 2442–51.
  • 13
    Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 1998; 273: 24052–6.
  • 14
    Fincham VJ, Chudleigh A, Frame MC. Regulation of p190 Rho-GAP by v-Src is linked to cytoskeletal disruption during transformation. J Cell Sci 1999; 112: 947–56.
  • 15
    Sheng H, Shao J, DuBois RN. Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem 2001; 276: 14498–504.
  • 16
    Chen G, Hitomi M, Han J, Stacey DW. The p38 pathway provides negative feedback for Ras proliferative signaling. J Biol Chem 2000; 275: 38973–80.
  • 17
    Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 1990; 87: 3042–6.
  • 18
    Fridman M, Tikoo A, Varga M, Murphy A, Nur EKMS, Maruta H. The minimal fragments of c-Raf-1 and NF1 that can suppress v-Ha-Ras-induced malignant phenotype. J Biol Chem 1994; 269: 30105–8.
  • 19
    Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995; 374: 457–9.
  • 20
    Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, Ikawa Y, Ratzkin BJ, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 1998; 95: 13221–6.
  • 21
    Hiwasa T, Tokita H, Ike Y. Differential chemosensitivity in oncogene-transformed cells. J Exp Ther Oncol 1996; 1: 162–70.
  • 22
    Yusoff P, Lao DH, Ong SH, Wong ES, Lim J, Lo TL, Leong HF, Fong CW, Guy GR. Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J Biol Chem 2002; 277: 3195–201.
  • 23
    Schechtman D, Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 2001; 20: 6339–47.
  • 24
    McCahill A, Warwicker J, Bolger GB, Houslay MD, Yarwood SJ. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol 2002; 62: 1261–73.
  • 25
    Chu LY, Chen YH, Chuang NN. Dimerize RACK1 upon transformation with oncogenic ras. Biochem Biophys Res Commun 2005; 330: 474–82.
  • 26
    Besson A, Wilson TL, Yong VW. The anchoring protein RACK1 links protein kinase Cepsilon to integrin β chains. Requirements for adhesion and motility. J Biol Chem 2002; 277: 22073–84.
  • 27
    Ron D, Chen CH, Caldwell J, Jamieson L, Orr E, Mochly-Rosen D. Cloning of an intracellular receptor for protein kinase C: a homolog of the β subunit of G proteins. Proc Natl Acad Sci USA 1994; 91: 839–43.
  • 28
    Thorsen VA, Bjorndal B, Nolan G, Fukami MH, Bruland O, Lillehaug JR, Holmsen H. Expression of a peptide binding to receptor for activated C-kinase (RACK1) inhibits phorbol myristoyl acetate-stimulated phospholipase D activity in C3H/10T1/2 cells: dissociation of phospholipase D-mediated phosphatidylcholine breakdown from its synthesis. Biochim Biophys Acta 2000; 1487: 163–76.
  • 29
    Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 1997; 6: 235–44.
  • 30
    Swift S, Lorens J, Achacoso P, Nolan G. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. In: ColiganJE, StroberW, ShevachEM, KruisbeekAM, MarguliesDH, eds. Current protocols in immunology, vol. 10.28. New York: Wiley, 1999.
  • 31
    Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156–9.
  • 32
    Helleland C, Eiane SA, Berge RK, Holmsen H, Lillehaug JR. 1-(Carboxymethylthio)tetradecane attenuates PDGF- and TPA-induced c-fos mRNA expression and increases the formation of phosphatidylethanolamine with a shift from less to more polar molecular species in C3H/10T1/2 cells. Exp Cell Res 1997; 236: 330–40.
  • 33
    Bjorndal B, Helleland C, Lillehaug JR. Differential TPA and PDGF-BB effects on subcellular localisation of PKC α and β I in C3H/10T1/2 cells. Anticancer Res 2000; 20: 2633–40.
  • 34
    Bjorndal B, Helleland C, Boe SO, Gudbrandsen OA, Kalland KH, Bohov P, Berge RK, Lillehaug JR. Nuclear import of factors involved in signaling is inhibited in C3H/10T1/2 cells treated with tetradecylthioacetic acid. J Lipid Res 2002; 43: 1630–40.
  • 35
    Imai Y, Suzuki Y, Tohyama M, Wanaka A, Takagi T. Cloning and expression of a neural differentiation-associated gene, p205, in the embryonal carcinoma cell line P19 and in the developing mouse. Brain Res Mol Brain Res 1994; 24: 313–9.
  • 36
    Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995; 270: 14843–6.
  • 37
    Ron D, Jiang Z, Yao L, Vagts A, Diamond I, Gordon A. Coordinated movement of RACK1 with activated βIIPKC. J Biol Chem 1999; 274: 27039–46.
  • 38
    Thornton C, Tang KC, Phamluong K, Luong K, Vagts A, Nikanjam D, Yaka R, Ron D. Spatial and temporal regulation of RACK1 function and N-methyl-D-aspartate receptor activity through WD40 motif-mediated dimerization. J Biol Chem 2004; 279: 31357–64.
  • 39
    Guillemot F, Billault A, Auffray C. Physical linkage of a guanine nucleotide-binding protein-related gene to the chicken major histocompatibility complex. Proc Natl Acad Sci USA 1989; 86: 4594–8.
  • 40
    Liliental J, Chang DD. Rack1, a receptor for activated protein kinase C, interacts with integrin β subunit. J Biol Chem 1998; 273: 2379–83.
  • 41
    Hermanto U, Zong CS, Li W, Wang LH. RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol 2002; 22: 2345–65.
  • 42
    Kiely PA, Sant A, O'Connor R. RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death. J Biol Chem 2002; 277: 22581–9.
  • 43
    Croze E, Usacheva A, Asarnow D, Minshall RD, Perez HD, Colamonici O. Receptor for activated C-kinase (RACK-1), a WD motif-containing protein, specifically associates with the human type I IFN receptor. J Immunol 2000; 165: 5127–32.
  • 44
    Usacheva A, Smith R, Minshall R, Baida G, Seng S, Croze E, Colamonici O. The WD motif-containing protein receptor for activated protein kinase C (RACK1) is required for recruitment and activation of signal transducer and activator of transcription 1 through the type I interferon receptor. J Biol Chem 2001; 276: 22948–53.
  • 45
    Ozaki T, Watanabe K, Nakagawa T, Miyazaki K, Takahashi M, Nakagawara A. Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB. Oncogene 2003; 22: 3231–42.
  • 46
    Angenstein F, Evans AM, Settlage RE, Moran ST, Ling SC, Klintsova AY, Shabanowitz J, Hunt DF, Greenough WT. A receptor for activated C kinase is part of messenger ribonucleoprotein complexes associated with polyA-mRNAs in neurons. J Neurosci 2002; 22: 8827–37.
  • 47
    Nilsson J, Sengupta J, Frank J, Nissen P. Regulation of eukaryotic translation by the RACK1 protein: a platform for signalling molecules on the ribosome. EMBO Rep 2004; 5: 1137–41.
  • 48
    Sengupta J, Nilsson J, Gursky R, Spahn CM, Nissen P, Frank J. Identification of the versatile scaffold protein RACK1 on the eukaryotic ribosome by cryo-EM. Nat Struct Mol Biol 2004; 11: 957–62.
  • 49
    Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–9.
  • 50
    Saito A, Fujii G, Sato Y, Gotoh M, Sakamoto M, Toda G, Hirohashi S. Detection of genes expressed in primary colon cancers by in situ hybridisation: overexpression of RACK 1. Mol Pathol 2002; 55: 34–9.
  • 51
    Berns H, Humar R, Hengerer B, Kiefer FN, Battegay EJ. RACK1 is up-regulated in angiogenesis and human carcinomas. Faseb J 2000; 14: 2549–58.
  • 52
    Dell EJ, Connor J, Chen S, Stebbins EG, Skiba NP, Mochly-Rosen D, Hamm HE. The β γ subunit of heterotrimeric G proteins interacts with RACK1 and two other WD repeat proteins. J Biol Chem 2002; 277: 49888–95.
  • 53
    Guil S, de La Iglesia N, Fernandez-Larrea J, Cifuentes D, Ferrer JC, Guinovart JJ, Bach-Elias M. Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus. Cancer Res 2003; 63: 5178–87.
  • 54
    Ron D, Mochly-Rosen D. Agonists and antagonists of protein kinase C function, derived from its binding proteins. J Biol Chem 1994; 269: 21395–8.
  • 55
    Csukai M, Mochly-Rosen D. Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Pharmacol Res 1999; 39: 253–9.
  • 56
    Adler V, Qu Y, Smith SJ, Izotova L, Pestka S, Kung HF, Lin M, Friedman FK, Chie L, Chung D, Boutjdir M, Pincus MR. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway. Biochemistry 2005; 44: 10784–95.
  • 57
    Lopez-Bergami P, Habelhah H, Bhoumik A, Zhang W, Wang LH, Ronai Z. RACK1 mediates activation of JNK by protein kinase C [corrected]. Mol Cell 2005; 19: 309–20.
  • 58
    Thorsen VA, Vorland M, Bjorndal B, Bruland O, Holmsen H, Lillehaug JR. Participation of phospholipase D and α/β-protein kinase C in growth factor-induced signalling in C3H10T1/2 fibroblasts. Biochim Biophys Acta 2003; 1632: 62–71.
View Full Article (HTML) Get PDF (746K)